A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma

NCT06261359 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG: CEND-1
DRUG: Gemcitabine
DRUG: Nab paclitaxel

Sponsor

Qilu Pharmaceutical Co., Ltd.